By June Kinoshita, FSHD Society The pharmaceutical industry is showing a growing interest in developing therapies for facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disorder affecting an estimated one million… Read More »
Big pharmas show growing interest in FSHD
Changemaker: Marisa Spain
Advocacy with humor and hacks Marisa Spain has a knack for making everyday advocacy both fun and impactful. Based in southeastern Michigan, Marisa brings fresh energy to accessibility awareness with… Read More »
XPRIZE for FSHD research
SOLVE FSHD, a venture philanthropic organization established to catalyze innovation in Facioscapulohumeral muscular dystrophy (FSHD) research, is partnering with the nonprofit organization XPRIZE Foundation to host a global competition to… Read More »
Changemaker: Archer Sverdrup
Building an early-onset community Meet Archer Sverdrup, a St. Louis native with a love for power soccer, arts and crafts, and hanging out with their loyal German Shepherd, Blue. Archer… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »